Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial.

AIMS To evaluate the efficacy of combining the dual endothelin receptor antagonist, bosentan, and the phosfodiesterase-5-inhibitor, sildenafil, in patients with Eisenmenger syndrome. METHODS AND RESULTS The study was a randomized, placebo-controlled, double-blinded, cross-over design. Patients with Eisenmenger syndrome (n = 21) were treated open label with bosentan for 9 months. After 3 months, sildenafil/placebo was added for 3 months, and a cross-over was performed for the last 3 months. At baseline and after 3, 6, and 9 months, patients were examined with 6 min walk test, oxygen saturations, N-terminal pro-brain natriuretic peptide, New York Heart Association (NYHA) classification, cardiac catheterization, and magnetic resonance imaging. The primary endpoint was changed in 6 min walk distance (MWD). Bosentan improved the 6 MWD (377 vs. 414 m, P = 0.001), pulmonary vascular resistance (PVR) (28 vs. 22 wood, P = 0.01), and pulmonary blood flow (2.6 vs. 3.5 L/min, P = 0.01). Adding sildenafil to bosentan did not improve the 6 MWD significantly (21 vs. 8 m, P = 0.48), but increased saturation at rest (2.9 vs. -1.8%, P < 0.01). CONCLUSION In Eisenmenger syndrome, treatment with bosentan significantly improved walking distance, pulmonary blood flow, and PVR. Adding sildenafil to bosentan did not significantly improve walking distance but did increase saturation at rest. http://www.ClinicalTrial.gov: NCT00303004.

[1]  T. Fleming,et al.  Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. , 2008, Annals of internal medicine.

[2]  M. Gatzoulis,et al.  Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study. , 2008, International journal of cardiology.

[3]  E. Chau,et al.  Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension. , 2007, International journal of cardiology.

[4]  K. Dimopoulos,et al.  Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease , 2007, Heart.

[5]  A. Zaiman,et al.  Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension , 2007, European Respiratory Journal.

[6]  A. Toscano,et al.  Bosentan and sildenafil: Should the combination therapy be a valid alternative in childhood to prostacyclin infusion? , 2007, Pediatric transplantation.

[7]  P. Engelfriet,et al.  Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease , 2006, Heart.

[8]  R. Barst,et al.  Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil , 2006, European Respiratory Journal.

[9]  R. Barst,et al.  Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. , 2006, American journal of respiratory and critical care medicine.

[10]  F. Fedele,et al.  Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical, and haemodynamic effect , 2006, Heart.

[11]  J. Granton,et al.  Eisenmenger syndrome and atrial septal defect: nature or nurture? , 2006, The Canadian journal of cardiology.

[12]  C. Ricachinevsky,et al.  Treatment of pulmonary arterial hypertension. , 2006, Jornal de pediatria.

[13]  A. Ordóñez,et al.  Combination therapy with sildenafil and bosentan reverts severe pulmonary hypertension and allows heart transplantation: case report. , 2006, Transplantation proceedings.

[14]  M. Hoeper,et al.  Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension , 2006, European Respiratory Journal.

[15]  P. Ewert,et al.  First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension , 2006, European journal of clinical investigation.

[16]  A. Arroliga,et al.  Long-term results after addition of sildenafil in idiopathic PAH patients on bosentan. , 2006, Southern medical journal.

[17]  M. Gatzoulis,et al.  Bosentan Therapy in Patients With Eisenmenger Syndrome: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study , 2006, Circulation.

[18]  M. Iglarz,et al.  Bosentan, Sildenafil, and Their Combination in the Monocrotaline Model of Pulmonary Hypertension in Rats , 2006, Experimental biology and medicine.

[19]  R. Barst,et al.  Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. , 2006, Journal of the American College of Cardiology.

[20]  T. Fleming,et al.  Sildenafil citrate therapy for pulmonary arterial hypertension. , 2005, The New England journal of medicine.

[21]  A. Boobis,et al.  Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. , 2005, British journal of clinical pharmacology.

[22]  M. Behrends,et al.  Combination of sildenafil and bosentan for nitric oxide withdrawal. , 2005, European Journal of Anaesthesiology.

[23]  T. Welte,et al.  Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension , 2004, European Respiratory Journal.

[24]  M. Humbert,et al.  Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 , 2004, European Respiratory Journal.

[25]  B. Raju,et al.  Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. , 2004, Journal of the American College of Cardiology.

[26]  A. Torbicki,et al.  Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. , 2003, Journal of the American College of Cardiology.

[27]  S. Rich,et al.  Efficacy and Safety of Treprostinil: An Epoprostenol Analog for Primary Pulmonary Hypertension , 2003, Journal of cardiovascular pharmacology.

[28]  W. Seeger,et al.  Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial , 2002, The Lancet.

[29]  W. Seeger,et al.  Inhaled iloprost for severe pulmonary hypertension. , 2002, The New England journal of medicine.

[30]  W. Seeger,et al.  Combination Therapy with Oral Sildenafil and Inhaled Iloprost for Severe Pulmonary Hypertension , 2002, Annals of Internal Medicine.

[31]  S. Rich,et al.  Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. , 2002, American journal of respiratory and critical care medicine.

[32]  E. Michelakis,et al.  Oral Sildenafil Is an Effective and Specific Pulmonary Vasodilator in Patients With Pulmonary Arterial Hypertension: Comparison With Inhaled Nitric Oxide , 2002, Circulation.

[33]  Avid,et al.  BOSENTAN THERAPY FOR PULMONARY ARTERIAL HYPERTENSION , 2002 .

[34]  D. Badesch,et al.  Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study , 2001, The Lancet.

[35]  S. Narumiya,et al.  Prostanoid receptors: structures, properties, and functions. , 1999, Physiological reviews.

[36]  W. dodds.  Instrumentation and methods for intraluminal esophageal manometry. , 1976, Archives of internal medicine.